Tianyin Pharmaceutical provides further updates on Gingko Mihuan Oral Liquid

Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today provided further updates on the business development of its flagship product: Gingko Mihuan Oral Liquid (GMOL) with the SFDA approval number: H20013079.

GMOL is a prescription medicine that targets cardiovascular indications such as strokes, coronary heart diseases, angina as well as reduces the risks of age-related cardiovascular ailments. Additional information regarding GMOL can also be accessed at the official website of SFDA at www.sfda.gov.cn, (Chinese version) or http://baike.baidu.com/view/3029034.htm.

In July 2013, GMOL was awarded Provincial Essential Drug List (PEDL) status at Guangdong Province, one of the major provinces of China with population over 100 million (http://finance.qq.com/a/20110430/000490.htm). This is the fifth province that awarded PEDL status to TPI's GMOL after its PEDL listings at Henan Province, Shandong Province, Sichuan Province and the City of Chongqing (Directly Governed City, the same status as provinces). The combined population of these regions is estimated at approximately 330 million (http://baike.baidu.com/view/244361.htm#2).

Under the ongoing healthcare reform, PEDL listing ensures the full coverage of the costs for the patients who use the PEDL drugs. As a result, national and provincial EDL listings could substantiate the market development for these products.